For Q1 FY2026 ended March 31, 2026, Immunome reported no revenue, a net loss of $53.8 million, and an operating loss of $59.3 million. Diluted EPS was -$0.48. The company held $582.7 million in cash and $588.7 million in equity, with no long-term debt.
•Revenue was $0, down 100% year-over-year.
•Net loss widened to $53.8 million from $41.6 million in the prior year quarter.
•Operating loss increased to $59.3 million, up 32.9% year-over-year.
•Cash and cash equivalents totaled $582.7 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Immunome, Inc., a biotechnology company provides the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. is a biotechnology company focused on the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates (ADCs) and other oncology therapeutics in the United States. Its lead clinical asset is Varegacestat, a gamma secretase inhibitor currently in Phase 3 clinical trials for the treatment of desmoid tumors. Additionally, the company is developing IM-1021, a receptor tyrosine kinase-like orphan receptor 1 ADC in Phase 1 trials. Preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy, and solid tumor ADC candidates IM-1617, IM-1340, and IM-1335.
On which exchange is Immunome (IMNM) listed and in what currency?
Immunome, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol IMNM. The company operates in the United States and its stock is traded in US Dollars (USD). As a US-based biotechnology firm, its financial reporting and market transactions are conducted in USD, making it accessible to investors trading on US exchanges.
What sector and industry does Immunome (IMNM) belong to?
Immunome, Inc. operates within the Healthcare sector, specifically in the Biotechnology industry. This classification reflects the company's focus on developing innovative therapies for oncology, including antibody-drug conjugates and targeted radioligand therapies. Biotechnology companies like Immunome engage in research and development to create new drugs, often with a high-risk, high-reward profile, and are subject to regulatory approvals and clinical trial outcomes.
Where is Immunome (IMNM) headquartered and what markets does it serve?
Immunome, Inc. is headquartered in Bothell, Washington, United States. The company primarily serves the US market, as indicated by its description focusing on operations within the United States. Its research, development, and manufacturing activities are based in the US, and it targets patients with oncology indications such as desmoid tumors and solid tumors. While the company may eventually expand globally, its current focus is on the domestic market.
What is Immunome's (IMNM) business model and how does it generate revenue?
Immunome, Inc. generates revenue through the development and potential commercialization of its oncology therapeutics, including antibody-drug conjugates (ADCs) and targeted therapies. The company's business model involves advancing its pipeline through clinical trials and seeking regulatory approval for its drug candidates. Its lead asset, Varegacestat, is in Phase 3 trials for desmoid tumors, and if approved, would generate sales. Additionally, Immunome may enter into partnerships or licensing agreements for its preclinical assets like IM-3050, IM-1617, IM-1340, and IM-1335. The company also focuses on manufacturing its own products, which could provide a competitive edge. However, as a biotechnology firm, it may currently operate at a loss while investing heavily in R&D.